Sanofi has entered into a definitive agreement to acquire and Ablynx, a biopharma company focused on the discovery and development of Nanobodies, for approximately $4.8 billion. The transaction was approved by both boards of directors.   The acquisition is part of Sanofi’s innovation efforts focused on technologies addressing multiple disease targets with single multi-specific molecules.   Nanobodies are a new class of next-gen biologics. Ablynx’s nanobody technology supports an extens...